Taro Pharmaceutical Industries Stock Price, News & Analysis (NYSE:TARO)

$105.30 0.41 (0.39 %)
(As of 01/18/2018 02:13 PM ET)
Previous Close$104.89
Today's Range$104.33 - $105.92
52-Week Range$94.00 - $128.46
Volume49,100 shs
Average Volume72,127 shs
Market Capitalization$4.21 billion
P/E Ratio12.97
Dividend YieldN/A
Beta0.63

About Taro Pharmaceutical Industries (NYSE:TARO)

Taro Pharmaceutical Industries logoTaro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:TARO
CUSIPN/A
Phone972-4847-5700

Debt

Debt-to-Equity RatioN/A
Current Ratio9.56%
Quick Ratio8.82%

Price-To-Earnings

Trailing P/E Ratio12.9679962660053
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$879.39 million
Price / Sales4.80
Cash Flow$11.69 per share
Price / Cash9.01
Book Value$51.19 per share
Price / Book2.06

Profitability

Trailing EPS$8.12
Net Income$456.35 million
Net Margins44.07%
Return on Equity15.66%
Return on Assets14.18%

Miscellaneous

EmployeesN/A
Outstanding Shares40,100,000

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) issued its quarterly earnings results on Tuesday, November, 7th. The company reported $1.30 EPS for the quarter. Taro Pharmaceutical Industries had a return on equity of 15.66% and a net margin of 44.07%. View Taro Pharmaceutical Industries' Earnings History.

When will Taro Pharmaceutical Industries make its next earnings announcement?

Taro Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, February, 8th 2018. View Earnings Estimates for Taro Pharmaceutical Industries.

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a decrease in short interest in December. As of December 15th, there was short interest totalling 869,027 shares, a decrease of 42.2% from the November 30th total of 1,502,780 shares. Based on an average trading volume of 126,816 shares, the short-interest ratio is presently 6.9 days. Approximately 8.2% of the shares of the company are short sold.

Who are some of Taro Pharmaceutical Industries' key competitors?

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the folowing people:

  • Dilip Shantilal Shanghvi, Chairman of the Board (Age 62)
  • Uday Baldota, Chief Executive Officer, Director (Age 47)
  • Abhay Gandhi, Vice Chairman of the Board (Age 52)
  • Mariano Balaguer, Chief Financial Officer, Chief Accounting Officer, Vice President (Age 44)
  • Stephen Manzano Esq., Group Vice President, General Counsel, Secretary, Corporate Compliance (Age 52)
  • Itamar Karsenti, Vice President - Head of Operations, Haifa (Age 45)
  • Chantal LeBlanc, Vice President - Global Quality (Age 54)
  • Daryl LeSueur, Vice President - Head of Operations, Brampton, Canada (Age 54)
  • Michael Perfetto, Group Vice President and Chief Commercial Officer of the Generic Rx and OTC Business (Age 56)
  • Michael Teiler, Group Vice President - Portfolio Management (Age 54)

Who owns Taro Pharmaceutical Industries stock?

Taro Pharmaceutical Industries' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (0.27%), Schwab Charles Investment Management Inc. (0.01%) and Bank of Montreal Can (0.00%). View Institutional Ownership Trends for Taro Pharmaceutical Industries.

Who sold Taro Pharmaceutical Industries stock? Who is selling Taro Pharmaceutical Industries stock?

Taro Pharmaceutical Industries' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Taro Pharmaceutical Industries.

Who bought Taro Pharmaceutical Industries stock? Who is buying Taro Pharmaceutical Industries stock?

Taro Pharmaceutical Industries' stock was acquired by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for Taro Pharmaceutical Industries.

How do I buy Taro Pharmaceutical Industries stock?

Shares of Taro Pharmaceutical Industries can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of Taro Pharmaceutical Industries stock can currently be purchased for approximately $105.30.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $4.21 billion and generates $879.39 million in revenue each year. The company earns $456.35 million in net income (profit) each year or $8.12 on an earnings per share basis.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKTOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]


MarketBeat Community Rating for Taro Pharmaceutical Industries (TARO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about Taro Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Taro Pharmaceutical Industries (NYSE:TARO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Taro Pharmaceutical Industries (NYSE:TARO) Consensus Price Target History

Price Target History for Taro Pharmaceutical Industries (NYSE:TARO)

Taro Pharmaceutical Industries (NYSE:TARO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017Credit Suisse GroupDowngradeOutperform -> NeutralLowView Rating Details
(Data available from 1/18/2016 forward)

Earnings

Taro Pharmaceutical Industries (NYSE:TARO) Earnings History and Estimates Chart

Earnings by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Taro Pharmaceutical Industries (NYSE TARO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018N/AView Earnings Details
11/7/2017Q2 2018$1.30ViewN/AView Earnings Details
8/8/2017Q1 2018$1.35ViewN/AView Earnings Details
5/22/2017Q4$2.05$196.41 millionViewN/AView Earnings Details
2/9/2017Q3 2017$3.42ViewN/AView Earnings Details
11/8/2016Q2 2017$3.00ViewListenView Earnings Details
8/10/2016Q1$2.59$215.30 million$233.80 millionViewN/AView Earnings Details
5/26/2016Q4$2.68$265.07 millionViewListenView Earnings Details
2/10/2016Q316$4.41$974.38 million$258.30 millionViewN/AView Earnings Details
11/3/2015Q2 2016$3.11ViewN/AView Earnings Details
8/6/2015Q116$2.42$1.01 billion$215.30 millionViewN/AView Earnings Details
5/26/2015Q415$3.56$881.79 million$244.18 millionViewListenView Earnings Details
2/10/2015Q315$3.33$213.60 million$237.70 millionViewN/AView Earnings Details
11/9/2014Q2 2015$3.35ViewN/AView Earnings Details
8/7/2014Q1 2015$0.98ViewN/AView Earnings Details
5/27/2014Q4$5.93$2.10$165.13 million$187.20 millionViewN/AView Earnings Details
2/10/2014Q214$2.59$185.70 million$213.60 millionViewN/AView Earnings Details
11/12/2013Q3$2.15ViewN/AView Earnings Details
8/7/2013Q114$1.32$159.15 million$153.20 millionViewN/AView Earnings Details
5/23/2013Q4 2013$1.10$145.00 million$165.10 millionViewN/AView Earnings Details
2/4/2013Q3 2013$1.98ViewN/AView Earnings Details
11/1/2012Q213$1.46$138.25 million$160.97 millionViewN/AView Earnings Details
8/6/2012Q1 2013$1.41ViewN/AView Earnings Details
5/24/2012Q4 2012$1.06ViewN/AView Earnings Details
2/10/2012Q3 2012$1.42ViewN/AView Earnings Details
11/10/2011Q2 2012$1.31ViewN/AView Earnings Details
7/26/2011Q1 2012$0.81ViewN/AView Earnings Details
5/26/2011Q4 2011$0.58ViewN/AView Earnings Details
1/28/2011Q3 2011$0.11ViewN/AView Earnings Details
10/29/2010Q2 2011$0.46ViewN/AView Earnings Details
8/23/2010Q1 2011$0.46ViewN/AView Earnings Details
6/14/2010Q4 2010$0.25ViewN/AView Earnings Details
12/2/2009Q2 2010$0.24ViewN/AView Earnings Details
8/10/2009Q1 2010$0.31ViewN/AView Earnings Details
5/22/2009Q4 2009$0.27ViewN/AView Earnings Details
2/10/2009Q3 2009$0.65ViewN/AView Earnings Details
11/11/2008Q2 2009$0.31ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Taro Pharmaceutical Industries (NYSE:TARO) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Taro Pharmaceutical Industries (NYSE:TARO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Taro Pharmaceutical Industries (NYSE TARO)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Taro Pharmaceutical Industries (NYSE TARO) News Headlines

Source:
DateHeadline
Short Interest in Taro Pharmaceutical Industries Ltd. (TARO) Decreases By 42.2%Short Interest in Taro Pharmaceutical Industries Ltd. (TARO) Decreases By 42.2%
www.americanbankingnews.com - January 4 at 1:16 AM
Is It Too Late To Buy Taro Pharmaceutical Industries Ltd (NYSE:TARO)?Is It Too Late To Buy Taro Pharmaceutical Industries Ltd (NYSE:TARO)?
finance.yahoo.com - January 3 at 3:36 PM
How Taro Pharmaceutical Industries Ltd (NYSE:TARO) Delivered A Better ROE Than Its IndustryHow Taro Pharmaceutical Industries Ltd (NYSE:TARO) Delivered A Better ROE Than Its Industry
finance.yahoo.com - December 26 at 8:36 PM
Contrasting Taro Pharmaceutical Industries (TARO) & Neuralstem (CUR)Contrasting Taro Pharmaceutical Industries (TARO) & Neuralstem (CUR)
www.americanbankingnews.com - December 26 at 9:24 AM
ETFs with exposure to Taro Pharmaceutical Industries Ltd. : December 20, 2017ETFs with exposure to Taro Pharmaceutical Industries Ltd. : December 20, 2017
finance.yahoo.com - December 20 at 3:35 PM
Critical Survey: Collegium Pharmaceutical (COLL) & Taro Pharmaceutical Industries (TARO)Critical Survey: Collegium Pharmaceutical (COLL) & Taro Pharmaceutical Industries (TARO)
www.americanbankingnews.com - December 14 at 7:16 AM
Head-To-Head Review: Taro Pharmaceutical Industries (TARO) versus Veru (VERU)Head-To-Head Review: Taro Pharmaceutical Industries (TARO) versus Veru (VERU)
www.americanbankingnews.com - December 3 at 8:14 AM
ETFs with exposure to Taro Pharmaceutical Industries Ltd. : December 1, 2017ETFs with exposure to Taro Pharmaceutical Industries Ltd. : December 1, 2017
finance.yahoo.com - December 1 at 5:01 PM
Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q2, 2018 By the Numbers : November 30, 2017Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q2, 2018 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 12:08 PM
Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : November 24, 2017Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : November 24, 2017
finance.yahoo.com - November 24 at 6:14 PM
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : November 23, 2017Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : November 23, 2017
finance.yahoo.com - November 23 at 4:21 PM
ETFs with exposure to Taro Pharmaceutical Industries Ltd. : November 16, 2017ETFs with exposure to Taro Pharmaceutical Industries Ltd. : November 16, 2017
finance.yahoo.com - November 18 at 9:10 AM
Taro Pharmaceutical Industries Earns RS Rating UpgradeTaro Pharmaceutical Industries Earns RS Rating Upgrade
finance.yahoo.com - November 14 at 8:29 AM
Taro Provides Results for September 30, 2017 | Business Wire - Business Wire (press release)Taro Provides Results for September 30, 2017 | Business Wire - Business Wire (press release)
www.businesswire.com - November 9 at 2:23 PM
Taro Pharmaceutical Industries (TARO) CEO Uday Vijaykumar Baldota on Q2 2018 Results - Earnings Call Transcript - Seeking AlphaTaro Pharmaceutical Industries' (TARO) CEO Uday Vijaykumar Baldota on Q2 2018 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 9 at 2:23 PM
Edited Transcript of TARO earnings conference call or presentation 8-Nov-17 1:00pm GMTEdited Transcript of TARO earnings conference call or presentation 8-Nov-17 1:00pm GMT
finance.yahoo.com - November 9 at 2:23 PM
Taro Pharmaceutical Industries Ltd.: Leads amongst peers with strong fundamentalsTaro Pharmaceutical Industries Ltd.: Leads amongst peers with strong fundamentals
finance.yahoo.com - November 9 at 2:23 PM
Financial Survey: Taro Pharmaceutical Industries (TARO) versus Akorn (AKRX)Financial Survey: Taro Pharmaceutical Industries (TARO) versus Akorn (AKRX)
www.americanbankingnews.com - November 7 at 11:10 PM
Taro to Announce Second Quarter Results on November 7, 2017Taro to Announce Second Quarter Results on November 7, 2017
finance.yahoo.com - October 31 at 10:21 AM
Taro Pharmaceutical Industries Ltd. (TARO) to Release Earnings on MondayTaro Pharmaceutical Industries Ltd. (TARO) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 9:36 AM
Contrasting Taro Pharmaceutical Industries (TARO) and Its PeersContrasting Taro Pharmaceutical Industries (TARO) and Its Peers
www.americanbankingnews.com - October 29 at 1:08 AM
Contrasting Taro Pharmaceutical Industries (TARO) and The CompetitionContrasting Taro Pharmaceutical Industries (TARO) and The Competition
www.americanbankingnews.com - October 22 at 2:08 PM
Shares of large generic drugmakers fallShares of large generic drugmakers fall
www.marketwatch.com - October 19 at 9:36 AM
Shares of large generic drugmakers fallShares of large generic drugmakers fall
www.marketwatch.com - October 19 at 9:36 AM
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : October 19, 2017Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : October 19, 2017
finance.yahoo.com - October 19 at 9:36 AM
Taro Pharmaceutical Industries Ltd. (TARO) Downgraded to Hold at BidaskClubTaro Pharmaceutical Industries Ltd. (TARO) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - October 15 at 2:06 PM
Does Taro Pharmaceutical Industries Ltd’s (TARO) PE Ratio Signal A Buying Opportunity?Does Taro Pharmaceutical Industries Ltd’s (TARO) PE Ratio Signal A Buying Opportunity?
finance.yahoo.com - September 30 at 6:36 PM
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bullish Manner : TARO-US : September 22, 2017Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bullish Manner : TARO-US : September 22, 2017
finance.yahoo.com - September 23 at 9:50 AM
ETFs with exposure to Taro Pharmaceutical Industries Ltd. : September 14, 2017ETFs with exposure to Taro Pharmaceutical Industries Ltd. : September 14, 2017
finance.yahoo.com - September 15 at 9:37 AM
Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q1, 2018 By the Numbers : September 13, 2017Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q1, 2018 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 10:58 AM
Taro Announces Joining of CEOTaro Announces Joining of CEO
finance.yahoo.com - September 2 at 9:18 AM
Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : August 21, 2017Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : August 21, 2017
finance.yahoo.com - August 23 at 12:19 PM
See what the IHS Markit Score report has to say about Taro Pharmaceutical Industries Ltd.See what the IHS Markit Score report has to say about Taro Pharmaceutical Industries Ltd.
finance.yahoo.com - August 13 at 6:41 AM
Taro Pharmaceutical Industries Ltd. (TARO) Downgraded by TheStreet to C+Taro Pharmaceutical Industries Ltd. (TARO) Downgraded by TheStreet to C+
www.americanbankingnews.com - August 11 at 3:24 PM
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : August 9, 2017Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US : August 9, 2017
finance.yahoo.com - August 10 at 8:33 AM
IHS Markit Score upgrades Taro Pharmaceutical Industries Ltd to 71 out of 100, despite ranking positively in only one IHS Markit category.IHS Markit Score upgrades Taro Pharmaceutical Industries Ltd to 71 out of 100, despite ranking positively in only one IHS Markit category.
finance.yahoo.com - August 10 at 8:33 AM
Taro Provides Results for Quarter Ended June 2017Taro Provides Results for Quarter Ended June 2017
finance.yahoo.com - August 9 at 8:02 AM
Taro posts 1Q profitTaro posts 1Q profit
finance.yahoo.com - August 9 at 8:02 AM
Taro Pharmaceutical: Solid Cash-Rich Business With No Debt And A CatalystTaro Pharmaceutical: Solid Cash-Rich Business With No Debt And A Catalyst
seekingalpha.com - August 5 at 7:34 AM
Taro to Announce First Quarter Results on August 8, 2017Taro to Announce First Quarter Results on August 8, 2017
finance.yahoo.com - August 3 at 7:47 AM
 Taro Pharmaceutical Industries Ltd. (TARO) Given Average Rating of "" by Brokerages Taro Pharmaceutical Industries Ltd. (TARO) Given Average Rating of "" by Brokerages
www.americanbankingnews.com - August 2 at 10:30 AM
Taro Pharmaceutical Industries Ltd. (TARO) Scheduled to Post Quarterly Earnings on TuesdayTaro Pharmaceutical Industries Ltd. (TARO) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:31 AM
 Taro Pharmaceutical Industries Ltd. (TARO) Receives Average Recommendation of "" from Brokerages Taro Pharmaceutical Industries Ltd. (TARO) Receives Average Recommendation of "" from Brokerages
www.americanbankingnews.com - July 30 at 10:42 AM
Taro Pharmaceutical Industries Ltd. (TARO) Lifted to B- at TheStreetTaro Pharmaceutical Industries Ltd. (TARO) Lifted to B- at TheStreet
www.americanbankingnews.com - July 23 at 9:26 PM
Contrasting Amphastar Pharmaceuticals (AMPH) & Taro Pharmaceutical Industries (TARO)Contrasting Amphastar Pharmaceuticals (AMPH) & Taro Pharmaceutical Industries (TARO)
www.americanbankingnews.com - July 15 at 10:04 PM
[$$] In Hot Pursuit of Indian Growth Stocks[$$] In Hot Pursuit of Indian Growth Stocks
finance.yahoo.com - July 14 at 8:56 AM
ETFs with exposure to Taro Pharmaceutical Industries Ltd. : July 12, 2017ETFs with exposure to Taro Pharmaceutical Industries Ltd. : July 12, 2017
finance.yahoo.com - July 13 at 10:14 AM
Sun Pharma Warns New Normal Will Push Down Its Sales Next YearSun Pharma Warns 'New Normal' Will Push Down Its Sales Next Year
www.bloomberg.com - May 27 at 6:09 AM
Oversold Conditions For Taro Pharmaceutical Industries (TARO)Oversold Conditions For Taro Pharmaceutical Industries (TARO)
www.nasdaq.com - May 25 at 4:05 AM
Crescita Therapeutics™ Announces 2017 First Quarter ResultsCrescita Therapeutics™ Announces 2017 First Quarter Results
www.streetinsider.com - May 16 at 8:49 AM

SEC Filings

Taro Pharmaceutical Industries (NYSE:TARO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Taro Pharmaceutical Industries (NYSE:TARO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Taro Pharmaceutical Industries (NYSE TARO) Stock Chart for Thursday, January, 18, 2018

Loading chart…

This page was last updated on 1/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.